• 1.

    Row PG, et al. Membranous nephropathy. Long-term follow-up and association with neoplasia. Q J Med 1975; 44:207239. https://doi.org/10.1093/oxfordjournals.qjmed.a067422

    • Search Google Scholar
    • Export Citation
  • 2.

    Cahen R, et al. Aetiology of membranous glomerulonephritis: A prospective study of 82 adult patients. Nephrol Dial Transplant 1989; 4:172180. doi: 10.1093/oxfordjournals.ndt.a091852

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Thet Z, et al. Critical evaluation of cancer risks in glomerular disease. Transl Oncol [published online ahead of print February 24, 2022]. doi: 10.1016/j.tranon.2022.101376; https://www.sciencedirect.com/science/article/pii/S1936523322000389?via%3Dihub

    • Search Google Scholar
    • Export Citation
  • 4.

    Leeaphorn N, et al. Prevalence of cancer in membranous nephropathy: A systematic review and meta-analysis of observational studies. Am J Nephrol 2014; 40:2935. doi: 10.1159/000364782

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Bjørneklett R, et al. Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis 2007; 50:396403. doi: 10.1053/j.ajkd.2007.06.003

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Zhang D, et al. Clinicopathological features in membranous nephropathy with cancer: A retrospective single-center study and literature review. Int J Biol Markers 2019; 34:406413. doi: 10.1177/1724600819882698

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Qu Z, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant 2012; 27:19311937. doi: 10.1093/ndt/gfr534

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Heaf JG, et al. Quantification of cancer risk in glomerulonephritis. BMC Nephrol 2018; 19:27. doi: 10.1186/s12882-018-0828-2

  • 9.

    Pani A, et al. Glomerular diseases and cancer: Evaluation of underlying malignancy. J Nephrol 2016; 29:143152. doi: 10.1007/s40620-015-0234-9

  • 10.

    Nissan E, et al. The usefulness of [18F]FDG-PET/CT in detecting and managing cancers with unknown primary site depends on histological subtype. Sci Rep 2021; 11:17732. doi: 10.1038/s41598-021-96451-z

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Caza TN, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int 2021; 99:967976. doi: 10.1016/j.kint.2020.07.039

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Khan MB, et al. Complete resolution of paraneoplastic membranous nephropathy following curative therapy of triple-negative breast cancer. Cureus 2021; 13:e18125. doi: 10.7759/cureus.18125

    • Search Google Scholar
    • Export Citation
  • 13.

    Adlington D, et al. Remission of membranous nephropathy after treatment of localised prostate cancer. Case Rep Nephrol Dial 2019; 9:7984. doi: 10.1159/000500948; https://core.ac.uk/download/pdf/237441013.pdf

    • Crossref
    • Search Google Scholar
    • Export Citation

Malignancy-Related Membranous Nephropathy

  • 1 Prabhat Chauhan, MBBS, MD, DM, is Assistant Professor with Indian Naval Hospital Ship (INHS), ASVINI, Mumbai, India. Raja Ramachandran, MBBS, MD, DM, is Associate Professor with the Department of Nephrology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India.
Restricted access

The prevalence of malignancy in patients with membranous nephropathy (MN) ranges from 4% to 10% (1, 2). In adults, MN is the most common cause of nephrotic syndrome outside of diabetes and is well described but not well studied in patients with cancer.

In a recent article by Thet and colleagues (3) in Translational Oncology, the authors impart on an update on cancer risks in patients with a glomerular diseases. Thet et al. (3) used MN as a prototype to understand malignancy-related glomerular disease. Malignancy-related MN is a disease of

Save